322 related articles for article (PubMed ID: 35053443)
1. Regulation of Bcl-2 Family Proteins in Estrogen Receptor-Positive Breast Cancer and Their Implications in Endocrine Therapy.
Kawiak A; Kostecka A
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053443
[TBL] [Abstract][Full Text] [Related]
2. Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers.
Williams MM; Lee L; Werfel T; Joly MMM; Hicks DJ; Rahman B; Elion D; McKernan C; Sanchez V; Estrada MV; Massarweh S; Elledge R; Duvall C; Cook RS
Cell Death Dis; 2018 Jan; 9(2):21. PubMed ID: 29343814
[TBL] [Abstract][Full Text] [Related]
3. Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.
Merino D; Lok SW; Visvader JE; Lindeman GJ
Oncogene; 2016 Apr; 35(15):1877-87. PubMed ID: 26257067
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer.
Zhao M; Ramaswamy B
World J Clin Oncol; 2014 Aug; 5(3):248-62. PubMed ID: 25114842
[TBL] [Abstract][Full Text] [Related]
5. Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugs.
Diepstraten ST; Young S; La Marca JE; Wang Z; Kluck RM; Strasser A; Kelly GL
Cell Death Differ; 2023 Apr; 30(4):1005-1017. PubMed ID: 36755070
[TBL] [Abstract][Full Text] [Related]
6. Noxa and Mcl-1 expression influence the sensitivity to BH3-mimetics that target Bcl-xL in patient-derived glioma stem cells.
Vera MB; Morris-Hanon O; Nogueiras GI; Ripari LB; Esquivel MI; Perez-Castro C; Romorini L; Sevlever GE; Scassa ME; Videla-Richardson GA
Sci Rep; 2022 Oct; 12(1):17729. PubMed ID: 36273072
[TBL] [Abstract][Full Text] [Related]
7. Pro-apoptotic activity of BH3-only proteins and BH3 mimetics: from theory to potential cancer therapy.
Hartman ML; Czyz M
Anticancer Agents Med Chem; 2012 Oct; 12(8):966-81. PubMed ID: 22263800
[TBL] [Abstract][Full Text] [Related]
8. BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-X
Greaves G; Milani M; Butterworth M; Carter RJ; Byrne DP; Eyers PA; Luo X; Cohen GM; Varadarajan S
Cell Death Differ; 2019 Jun; 26(6):1037-1047. PubMed ID: 30185825
[TBL] [Abstract][Full Text] [Related]
9. Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer.
Vallet S; Fan F; Malvestiti S; Pecherstorfer M; Sattler M; Schneeweiss A; Schulze-Bergkamen H; Opferman JT; Cardone MH; Jäger D; Podar K
Breast Cancer Res Treat; 2019 Feb; 173(3):585-596. PubMed ID: 30374681
[TBL] [Abstract][Full Text] [Related]
10. Estrogen Receptor Bio-Activities Determine Clinical Endocrine Treatment Options in Estrogen Receptor-Positive Breast Cancer.
Xia S; Lin Q
Technol Cancer Res Treat; 2022; 21():15330338221090351. PubMed ID: 35450488
[TBL] [Abstract][Full Text] [Related]
11. BH3 Mimetic Sensitivity of Colorectal Cancer Cell Lines in Correlation with Molecular Features Identifies Predictors of Response.
Zhang L; Ramesh P; Steinmetz M; Medema JP
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917026
[TBL] [Abstract][Full Text] [Related]
12. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
Massarweh S; Schiff R
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S15-24. PubMed ID: 17259554
[TBL] [Abstract][Full Text] [Related]
13. The carboxyl-terminal sequence of PUMA binds to both anti-apoptotic proteins and membranes.
Pemberton JM; Nguyen D; Osterlund EJ; Schormann W; Pogmore JP; Hirmiz N; Leber B; Andrews DW
Elife; 2023 Apr; 12():. PubMed ID: 37078707
[TBL] [Abstract][Full Text] [Related]
14. Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer.
Vaillant F; Merino D; Lee L; Breslin K; Pal B; Ritchie ME; Smyth GK; Christie M; Phillipson LJ; Burns CJ; Mann GB; Visvader JE; Lindeman GJ
Cancer Cell; 2013 Jul; 24(1):120-9. PubMed ID: 23845444
[TBL] [Abstract][Full Text] [Related]
15. Resistance to BH3 mimetic S1 in SCLC cells that up-regulate and phosphorylate Bcl-2 through ERK1/2.
Liu Y; Zhang Z; Song T; Liang F; Xie M; Sheng H
Br J Pharmacol; 2013 Aug; 169(7):1612-23. PubMed ID: 23651505
[TBL] [Abstract][Full Text] [Related]
16. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Raha P; Thomas S; Thurn KT; Park J; Munster PN
Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
[TBL] [Abstract][Full Text] [Related]
17. A direct comparison of selective BH3-mimetics reveals BCL-X
Bierbrauer A; Jacob M; Vogler M; Fulda S
Br J Cancer; 2020 May; 122(10):1544-1551. PubMed ID: 32203216
[TBL] [Abstract][Full Text] [Related]
18. Keratinocyte growth factor (KGF) regulates estrogen receptor-alpha (ER-alpha) expression and cell apoptosis via phosphatidylinositol 3-kinase (PI3K)/Akt pathway in human breast cancer cells.
Chang HL; Sugimoto Y; Liu S; Wang LS; Huang YW; Ye W; Lin YC
Anticancer Res; 2009 Aug; 29(8):3195-205. PubMed ID: 19661335
[TBL] [Abstract][Full Text] [Related]
19. Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML.
Ewald L; Dittmann J; Vogler M; Fulda S
Cell Death Dis; 2019 Dec; 10(12):917. PubMed ID: 31801941
[TBL] [Abstract][Full Text] [Related]
20. Bak and Bcl-xL Participate in Regulating Sensitivity of Solid Tumor Derived Cell Lines to Mcl-1 Inhibitors.
Senichkin VV; Pervushin NV; Zamaraev AV; Sazonova EV; Zuev AP; Streletskaia AY; Prikazchikova TA; Zatsepin TS; Kovaleva OV; Tchevkina EM; Zhivotovsky B; Kopeina GS
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]